stoxline Quote Chart Rank Option Currency Glossary
PhaseBio Pharmaceuticals, Inc. (PHAS)
0.0701  0 (0%)    06-04 16:00
Open: 0.0807
High: 0.092
Volume: 8,562,718
Pre. Close: 0.0701
Low: 0.0665
Market Cap: 0(M)
Technical analysis
2023-01-06 4:33:43 PM
Short term     
Mid term     
Targets 6-month :  0.11 1-year :  0.16
Resists First :  0.1 Second :  0.13
Pivot price 0.05
Supports First :  0.04 Second :  0.03
MAs MA(5) :  0.04 MA(20) :  0.06
MA(100) :  0.59 MA(250) :  1.03
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  5.1 D(3) :  4.5
RSI RSI(14): 32
52-week High :  2.7 Low :  0.04
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PHAS ] has closed above bottom band by 38.0%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.05 - 0.05 0.05 - 0.05
Low: 0.04 - 0.04 0.04 - 0.04
Close: 0.05 - 0.05 0.05 - 0.05
Company Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Headline News

Tue, 18 Jun 2024
PhaseBio Pharmaceuticals, Inc. (PHAS) Shares March Higher, Can It Continue? - Yahoo Movies UK

Mon, 24 Oct 2022
PhaseBio Files for Bankruptcy Following Blackstone-Backed Partner's Lawsuit - The Wall Street Journal

Mon, 24 Oct 2022
PhaseBio Files for Bankruptcy, Inks Deal to Sell Assets to Unnamed Company (Updated) - BioSpace

Mon, 24 Oct 2022
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code - Business Wire

Mon, 18 Apr 2022
Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B - Yahoo Finance

Tue, 08 Mar 2022
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 50 (M)
Held by Insiders 3.441e+007 (%)
Held by Institutions 6.7 (%)
Shares Short 1,470 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.0226e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -12 %
Return on Assets (ttm) 738.6 %
Return on Equity (ttm) -106.1 %
Qtrly Rev. Growth 818000 %
Gross Profit (p.s.) -34.15
Sales Per Share 0
EBITDA (p.s.) -3.18049e+007
Qtrly Earnings Growth -2.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -59 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.06
Stock Dividends
Dividend 0
Forward Dividend 2.07e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android